论文部分内容阅读
目的 研究Fas配体mRNA表达与大肠癌生物学行为及临床预后的关系。方法 应用原位杂交方法检测Fas配体mRNA在 5 2例大肠癌组织中的表达。结果 大肠癌Fas配体mRNA表达阳性率为 5 8% ( 3 0 / 5 2 )。存在癌周炎性反应的大肠癌组织中FasLmRNA阳性率为 2 5 % ( 3 / 12 ) ,而无癌周炎性反应的大肠癌阳性率为 68% ( 2 7/ 4 0 ) ,两者差异有显著性意义 (P <0 0 5 )。Fas配体mRNA表达在DukesB期组 3 8% ( 10 / 2 6) ,C期组为 73 % ( 16/ 2 2 ) ,D期组为 10 0 % ( 4 / 4 ) ,差异有显著性 (P <0 0 5 )。FasLmRNA阳性组术后 5年累积生存率为 5 0 % ( 15 / 3 0 ) ,明显低于阴性组 86% ( 19/ 2 2 ) ,两者差异有显著性意义 (P <0 0 5 )。结论 Fas配体对大肠癌临床分期和预后起重要作用。
Objective To study the relationship between Fas ligand mRNA expression and biological behavior and clinical prognosis of colorectal cancer. Methods In situ hybridization was used to detect the expression of Fas ligand mRNA in 52 cases of colorectal cancer. Results The positive rate of Fas ligand mRNA expression in colorectal cancer was 5 8% ( 30/52). The positive rate of FasL mRNA was 25% (3/12) in colorectal cancer tissues with pericarcinous inflammatory reaction, while the positive rate of colorectal cancer without pericarcinative inflammation was 68% (27/40). Significantly significant (P < 0 0 5). Fas ligand mRNA expression was 38% (10/26) in Dukes B stage group, 73% (16/22) in C stage group, and 10% (4/4) D stage group, the difference was significant ( P <0 0 5 ). The 5-year cumulative survival rate of FasL mRNA-positive group was 50% (15/30), which was significantly lower than that of negative group (86% (19/22)). There was a significant difference between the two groups (P < 0.05). Conclusion Fas ligand plays an important role in the clinical stage and prognosis of colorectal cancer.